Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA12 | O43570 | 2/20 | 0.61 |
| ▸ | CA3 | P07451 | 2/20 | 0.61 |
| ▸ | CA4 | P22748 | 2/20 | 0.61 |
| ▸ | CA6 | P23280 | 2/20 | 0.61 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | CA7 | P43166 | 2/20 | 0.61 |
| ▸ | CA9 | Q16790 | 2/20 | 0.61 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.61 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.50 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15575337 | 0.94 | SMN1; SMN2 (0.57) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL7629070 | 0.87 | SMN1; SMN2 (0.80) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL8080277 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL1804982 | 0.78 | SMN1; SMN2 (0.67) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL30960 | 0.78 | GAA (1.00) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL620156 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL709242 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL7020553 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL2442745 | 0.76 | CA1 (1.00) | SMN1; SMN2GAACA1CA2CA12 | |
| SCHEMBL2444494 | 0.76 | SMN1; SMN2 (0.64) | SMN1; SMN2GAACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2998288-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2610248-A1 | METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING A PALLADIUM COMPOUND | Teijin Pharma Limited (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-7968584-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1893581-B1 | SUBSTITUTED ARYLPYRAZOLES FOR USE AGAINST PARASITITES | PFIZER LTD (GB) | 2010-01-27 | — | — | EP | disclosed |
| EP-2091928-A2 | 3-(2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-2081893-A2 | SUBSTITUTED INDOLES | Auspex Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER INC. (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009078813-A1 | METHOD OF FORMING OSELTAMIVIR AND DERIVATIVES THEREOF | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2009-06-25 | — | — | WO | disclosed |
| US-7538134-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1954669-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | Auspex Pharmaceuticals Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008049116-A2 | SUBSTITUTED INDOLES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007064697-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060287365-A1 | Substituted arylpyrazoles | ZOETIS LLC | 2006-12-21 | — | — | US | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006034093-A2 | 3- (2-ACYLAMINO-1-HYDROXYETHYL)- MORPHOLINE DERIVATIVES AND THEIR USE AS BACE INHIBITORS | ELLI LILLY AND COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2002026697-A2 | AROMATIC DERIVATIVES WITH HIV INTEGRASE INHIBITORY PROPERTIES | PHARMACOR, INC. (CA) | 2002-04-04 | — | — | WO | disclosed |
| EP-0292800-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287365-A1 | Substituted arylpyrazoles | CYP3A4, CYP3A43, CYP4B1 | SMN1; SMN2 2801/4885GAA 774/4885CA1 3510/4885 |
| US-20090186924-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A4, CYP3A43, CYP4B1 | SMN1; SMN2 2801/4885GAA 774/4885CA1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.